In this first-in-human phase I trial of allogeneic CD70-targeting CAR-T cells for relapsed/refractory T cell lymphoma, 18 of 39 patients achieved an objective response, including 10 with PTCLs (4 CRs and 6 PRs). Here, CD70 is linked to T-cell non-Hodgkin lymphoma.